- Home
- JHG vs PRAX Comparison
JHG vs PRAX Comparison
Compare JHG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHG | PRAX |
|---|---|---|
| Founded | 1934 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JHG | PRAX |
|---|---|---|
| Price | $47.95 | $296.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $47.38 | ★ $374.64 |
| AVG Volume (30 Days) | ★ 2.3M | 586.2K |
| Earning Date | 01-30-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 33.81 | N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | ★ $2,663,300,000.00 | $7,463,000.00 |
| Revenue This Year | $13.17 | N/A |
| Revenue Next Year | $6.90 | $14,827.76 |
| P/E Ratio | $14.12 | ★ N/A |
| Revenue Growth | 14.14 | ★ 364.98 |
| 52 Week Low | $28.26 | $26.70 |
| 52 Week High | $49.42 | $317.72 |
Technical Indicators
Market Signals| Indicator | JHG | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 61.37 |
| Support Level | $47.68 | $266.93 |
| Resistance Level | $48.13 | $305.21 |
| Average True Range (ATR) | 0.23 | 15.46 |
| MACD | -0.08 | -3.49 |
| Stochastic Oscillator | 70.34 | 55.63 |
Price Performance
Historical ComparisonAbout JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.